Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Larry J. Dumont is active.

Publication


Featured researches published by Larry J. Dumont.


Transfusion | 2008

Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials

Larry J. Dumont; James P. AuBuchon

BACKGROUND: FDA requirements for recovery of radiolabeled red blood cells (RBCs) 24 hours after autologous reinfusion in normal subjects have evolved over time. This study defined the ability of currently available RBC systems to satisfy the most recently proposed criteria.


Transfusion | 2002

Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study

Larry J. Dumont; James P. AuBuchon; Pamela Whitley; Louise Herschel; Adrienne Johnson; Deanna McNeil; Sherrie Sawyer; Jill Roger

BACKGROUND: Bacterial screening may effectively reduce the morbidity and mortality risk associated with extended storage of platelets. Platelet viability then becomes the primary determinant of acceptable storage time. This study evaluates the effectiveness of platelets stored in plasma for 7 days.


Transfusion | 1996

Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)

Larry J. Dumont; Walter H. Dzik; Paolo Rebulla; Harvey Brandwein

Background: The increased use of white (WBC)‐reduced blood components has prompted many institutions to develop quality assurance programs directed to such component preparation processes. For consistent preparation of WBC‐reduced blood components that meet clinical needs as well as national standards, a program of process validation and control should be instituted. This involves controlling key factors that affect WBC reduction as well as periodic monitoring of the residual cellular content of components. Practical guidelines for the implementation of such a program are provided.


Vox Sanguinis | 2004

Platelet storage solution effects on the accuracy of laboratory tests for platelet function: a multi‐laboratory study

Tania VandenBroeke; Larry J. Dumont; S. Hunter; Janice Nixon; Scott Murphy; J. Roger; Louise Herschel; James P. AuBuchon; Hans Gulliksson; T. Dengler; V. Hornsey; Chris Prowse

Background and Objectives  Extent of shape change (ESC) and hypotonic shock response (HSR) have been widely used to characterize the in vitro function of platelets and have been shown to correlate with in vivo viability. These assays have been routinely performed using platelet‐poor plasma (PPP) as the test sample diluent. Because of the increasing popularity of storing platelets in synthetic media, it is important to understand the effects of using these synthetic media as test diluents for ESC and HSR measurements. The objective of this study was to determine the effect of using platelet storage solutions vs. plasma for the in vitro testing of ESC and HSR.


Transfusion | 2010

Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results.

Larry J. Dumont; Steven H. Kleinman; Murphy; Rebecca Lippincott; Robert Schuyler; Jaime Houghton; Peyton S. Metzel

BACKGROUND: The PASSPORT study was an FDA‐mandated surveillance of outdated 7‐day apheresis platelets (APs) to assess the bacterial culture release test (RT) performance and the chance of transfusing APs containing viable bacteria compared to untested 5‐day APs.


Transfusion | 2010

BLOOD COMPONENTS: Screening of single‐donor apheresis platelets for bacterial contamination: the PASSPORT study results

Larry J. Dumont; Steven H. Kleinman; James R. Murphy; Rebecca Lippincott; Robert Schuyler; Jaime Houghton; Peyton S. Metzel

BACKGROUND: The PASSPORT study was an FDA‐mandated surveillance of outdated 7‐day apheresis platelets (APs) to assess the bacterial culture release test (RT) performance and the chance of transfusing APs containing viable bacteria compared to untested 5‐day APs.


Transfusion | 2008

Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions : a systematic review

Nancy M. Heddle; Donald M. Arnold; Diana Boye; Kathryn E. Webert; Ilona Resz; Larry J. Dumont

BACKGROUND: A systematic review and meta‐analysis was performed to determine if there were differences between apheresis platelet concentrates (APCs) or platelets (PLTs) derived from whole blood (WBD) for the outcomes acute reactions, alloimmunization, refractoriness, corrected count increment (CCI), radiolabeled recovery and survival, time to next transfusion, and bleeding.


Transfusion | 2008

The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells

Tatsuro Yoshida; James P. AuBuchon; Larry J. Dumont; James D. Gorham; Sean C. Gifford; Kevin Y. Foster; Mark W. Bitensky

BACKGROUND: Red cell (RBC) storage can be extended to 9 weeks under anaerobic or alkaline conditions. Simultaneous use of these approaches has not provided additive benefit. Our objective was to determine whether anaerobic storage with acidified additive solution (AS) coupled with metabolic rejuvenation might further improve the benefits of anaerobic storage.


Transfusion Medicine Reviews | 2014

Metabolomics of ADSOL (AS-1) Red Blood Cell Storage

John D. Roback; Cassandra D. Josephson; Edmund K. Waller; James L. Newman; Sulaiman Karatela; Karan Uppal; Dean P. Jones; James C. Zimring; Larry J. Dumont

Population-based investigations suggest that red blood cells (RBCs) are therapeutically effective when collected, processed, and stored for up to 42 days under validated conditions before transfusion. However, some retrospective clinical studies have shown worse patient outcomes when transfused RBCs have been stored for the longest times. Furthermore, studies of RBC persistence in the circulation after transfusion have suggested that considerable donor-to-donor variability exists and may affect transfusion efficacy. To understand the limitations of current blood storage technologies and to develop approaches to improve RBC storage and transfusion efficacy, we investigated the global metabolic alterations that occur when RBCs are stored in AS-1 (AS1-RBC). Leukoreduced AS1-RBC units prepared from 9 volunteer research donors (12 total donated units) were serially sampled for metabolomics analysis over 42 days of refrigerated storage. Samples were tested by gas chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry, and specific biochemical compounds were identified by comparison to a library of purified standards. Over 3 experiments, 185 to 264 defined metabolites were quantified in stored RBC samples. Kinetic changes in these biochemicals confirmed known alterations in glycolysis and other pathways previously identified in RBCs stored in saline, adenine, glucose and mannitol solution (SAGM-RBC). Furthermore, we identified additional alterations not previously seen in SAGM-RBCs (eg, stable pentose phosphate pathway flux, progressive decreases in oxidized glutathione), and we delineated changes occurring in other metabolic pathways not previously studied (eg, S-adenosyl methionine cycle). These data are presented in the context of a detailed comparison with previous studies of SAGM-RBCs from human donors and murine AS1-RBCs. Global metabolic profiling of AS1-RBCs revealed a number of biochemical alterations in stored blood that may affect RBC viability during storage as well as therapeutic effectiveness of stored RBCs in transfusion recipients. These results provide future opportunities to more clearly pinpoint the metabolic defects during RBC storage, to identify biomarkers for donor screening and prerelease RBC testing, and to develop improved RBC storage solutions and methodologies.


Transfusion | 2006

In vitro pH effects on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative.

Larry J. Dumont; James P. AuBuchon; Hans Gulliksson; Sherrill J. Slichter; M. Dean Elfath; Stein Holme; James R. Murphy; Leslie Rose; Mark A. Popovsky; Scott Murphy

BACKGROUND: The pH environment of stored platelet (PLT) products is recognized as an important factor and is generally used as a key surrogate measure of PLT viability. It is the only in vitro measurement that has been translated into industry standards and regulatory rules or specifications for storage of PLT products. The objective of this study was to evaluate the effect of in vitro pH on the in vivo recovery and survival of autologous PLT products.

Collaboration


Dive into the Larry J. Dumont's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jose A. Cancelas

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Neeta Rugg

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Angelo D'Alessandro

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Deborah F. Dumont

Dartmouth–Hitchcock Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge